{"id":70,"date":"2008-11-13T11:32:00","date_gmt":"2008-11-13T11:32:00","guid":{"rendered":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html"},"modified":"2008-11-13T11:32:00","modified_gmt":"2008-11-13T11:32:00","slug":"astrazeneca-receives-approval-for-bipolar-drug","status":"publish","type":"post","link":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html","title":{"rendered":"AstraZeneca receives approval for bipolar drug"},"content":{"rendered":"Date: 11\/13\/2008<br \/><br \/>LONDON (AP) _ Pharmaceutical company AstraZeneca PLC said Thursday European regulators have approved a new version of its bipolar disorder drug Seroquel.<br \/><br \/>The drug company said a once-daily formulation, Seroquel XR, has been approved by the European Mutual Recognition Procedure for new indications in bipolar disorder and moderate to severe manic episodes in bipolar disorder.<br \/><br \/>Bipolar disorder causes dramatic mood swings, from deep depression to manic highs. AstraZeneca shares rose 1.7 percent to close at 2,837 pence ($41.55) in London.<br \/><br \/>Copyright 2008 The Associated Press.","protected":false},"excerpt":{"rendered":"<p>Date: 11\/13\/2008LONDON (AP) _ Pharmaceutical company AstraZeneca PLC said Thursday European regulators have approved a new version of its bipolar disorder drug Seroquel.The drug company said a once-daily formulation, Seroquel XR, has been approved by the European Mutual Recognition Procedure for new indications in bipolar disorder and moderate to severe manic episodes in bipolar disorder.Bipolar [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[100,251,169,297,294,296,295],"class_list":["post-70","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-astrazeneca","tag-bipolar-disorder","tag-drug-news","tag-manic-episodes","tag-manic-highs","tag-mood-swings","tag-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca receives approval for bipolar drug - Brain Injury Lawyer Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca receives approval for bipolar drug - Brain Injury Lawyer Blog\" \/>\n<meta property=\"og:description\" content=\"Date: 11\/13\/2008LONDON (AP) _ Pharmaceutical company AstraZeneca PLC said Thursday European regulators have approved a new version of its bipolar disorder drug Seroquel.The drug company said a once-daily formulation, Seroquel XR, has been approved by the European Mutual Recognition Procedure for new indications in bipolar disorder and moderate to severe manic episodes in bipolar disorder.Bipolar [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html\" \/>\n<meta property=\"og:site_name\" content=\"Brain Injury Lawyer Blog\" \/>\n<meta property=\"article:published_time\" content=\"2008-11-13T11:32:00+00:00\" \/>\n<meta name=\"author\" content=\"Gordon Johnson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gordon Johnson\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html\"},\"author\":{\"name\":\"Gordon Johnson\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#\\\/schema\\\/person\\\/3db3864e6ca028327e090439e0b4b262\"},\"headline\":\"AstraZeneca receives approval for bipolar drug\",\"datePublished\":\"2008-11-13T11:32:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html\"},\"wordCount\":87,\"commentCount\":0,\"keywords\":[\"AstraZeneca\",\"Bipolar disorder\",\"drug news\",\"manic episodes\",\"manic highs\",\"mood swings\",\"pharmaceuticals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html\",\"url\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html\",\"name\":\"AstraZeneca receives approval for bipolar drug - Brain Injury Lawyer Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#website\"},\"datePublished\":\"2008-11-13T11:32:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#\\\/schema\\\/person\\\/3db3864e6ca028327e090439e0b4b262\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/waiting.com\\\/blog\\\/2008\\\/11\\\/astrazeneca-receives-approval-for-bipolar-drug.html\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/waiting.com\\\/blog\\\/\",\"name\":\"Brain Injury Lawyer Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/waiting.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#\\\/schema\\\/person\\\/3db3864e6ca028327e090439e0b4b262\",\"name\":\"Gordon Johnson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g\",\"caption\":\"Gordon Johnson\"},\"sameAs\":[\"http:\\\/\\\/tbilaw.com\"],\"url\":\"https:\\\/\\\/waiting.com\\\/blog\\\/author\\\/gjohnson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca receives approval for bipolar drug - Brain Injury Lawyer Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca receives approval for bipolar drug - Brain Injury Lawyer Blog","og_description":"Date: 11\/13\/2008LONDON (AP) _ Pharmaceutical company AstraZeneca PLC said Thursday European regulators have approved a new version of its bipolar disorder drug Seroquel.The drug company said a once-daily formulation, Seroquel XR, has been approved by the European Mutual Recognition Procedure for new indications in bipolar disorder and moderate to severe manic episodes in bipolar disorder.Bipolar [&hellip;]","og_url":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html","og_site_name":"Brain Injury Lawyer Blog","article_published_time":"2008-11-13T11:32:00+00:00","author":"Gordon Johnson","twitter_misc":{"Written by":"Gordon Johnson"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html#article","isPartOf":{"@id":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html"},"author":{"name":"Gordon Johnson","@id":"https:\/\/waiting.com\/blog\/#\/schema\/person\/3db3864e6ca028327e090439e0b4b262"},"headline":"AstraZeneca receives approval for bipolar drug","datePublished":"2008-11-13T11:32:00+00:00","mainEntityOfPage":{"@id":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html"},"wordCount":87,"commentCount":0,"keywords":["AstraZeneca","Bipolar disorder","drug news","manic episodes","manic highs","mood swings","pharmaceuticals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html#respond"]}]},{"@type":"WebPage","@id":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html","url":"https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html","name":"AstraZeneca receives approval for bipolar drug - Brain Injury Lawyer Blog","isPartOf":{"@id":"https:\/\/waiting.com\/blog\/#website"},"datePublished":"2008-11-13T11:32:00+00:00","author":{"@id":"https:\/\/waiting.com\/blog\/#\/schema\/person\/3db3864e6ca028327e090439e0b4b262"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/waiting.com\/blog\/2008\/11\/astrazeneca-receives-approval-for-bipolar-drug.html"]}]},{"@type":"WebSite","@id":"https:\/\/waiting.com\/blog\/#website","url":"https:\/\/waiting.com\/blog\/","name":"Brain Injury Lawyer Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/waiting.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/waiting.com\/blog\/#\/schema\/person\/3db3864e6ca028327e090439e0b4b262","name":"Gordon Johnson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g","caption":"Gordon Johnson"},"sameAs":["http:\/\/tbilaw.com"],"url":"https:\/\/waiting.com\/blog\/author\/gjohnson"}]}},"_links":{"self":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts\/70","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/comments?post=70"}],"version-history":[{"count":0,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts\/70\/revisions"}],"wp:attachment":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/media?parent=70"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/categories?post=70"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/tags?post=70"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}